| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss on disposal of property and equipment | NaN | NaN | NaN | -67 |
| Change in fair value of warrant liability | NaN | 0 | 0 | 0 |
| Net loss | -14,456 | -15,156 | -12,792 | -32,030 |
| Depreciation and amortization | 83 | 85 | 81 | 157 |
| Noncash operating lease expense | 624 | 387 | 233 | 460 |
| Stock-based compensation | 3,823 | 2,482 | 2,569 | 4,987 |
| Accretion of premiums/discounts on marketable securities, net | 395 | 103 | -4 | 692 |
| Loss on disposal of property and equipment | -2 | 0 | -67 | NaN |
| Gain on sale of equipment | NaN | NaN | 0 | NaN |
| Gain on marketable securities | 0 | 6 | 0 | 6 |
| Prepaid expenses and other current assets | 1,616 | 2,504 | 1,165 | -273 |
| Other long-term assets | NaN | -9 | 0 | 6 |
| Accounts payable | 490 | 162 | -1,221 | 190 |
| Accrued expenses | -3,525 | 2,097 | 351 | -2,964 |
| Operating lease liabilities | -1,296 | -495 | -257 | -509 |
| Net cash used in operating activities | -16,266 | -13,042 | -12,197 | -30,073 |
| Purchase of property and equipment | 312 | 42 | 98 | 91 |
| Proceeds from sale of equipment | NaN | 0 | 0 | NaN |
| Purchases of marketable securities | 97,117 | 84,733 | 18,641 | 59,128 |
| Sales and maturities of marketable securities | 58,121 | 37,322 | 33,680 | 88,018 |
| Net cash provided by (used in) investing activities | -39,308 | -47,453 | 14,941 | 28,799 |
| Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs | NaN | NaN | NaN | 0 |
| Proceeds from issuance of common stock-IPO | NaN | 0 | 0 | NaN |
| Payments of deferred offering costs | 69 | 0 | 80 | 176 |
| Proceeds from issuance of common stock-At The Market Offering | NaN | 0 | 19,012 | NaN |
| Proceeds from employee stock purchase plan | NaN | 200 | 0 | 267 |
| Proceeds from issuance of common stock-Follow On Offering | NaN | 93,243 | NaN | NaN |
| Proceeds from exercise of stock options | 198 | 22 | 173 | 24 |
| Net cash provided by financing activities | 129 | 93,465 | 19,105 | 115 |
| Net increase (decrease) in cash and cash equivalents | -55,445 | 32,970 | 21,849 | -1,159 |
| Cash and cash equivalents at beginning of period | 75,603 | 42,633 | 21,943 | NaN |
| Cash and cash equivalents at end of period | 20,158 | 75,603 | 42,633 | NaN |
Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc. (CTNM)